Low Dose Cyclophosphamide Modulates Tumor Microenvironment by TGF-β Signaling Pathway
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Low Dose Cyclophosphamide Modulates Tumor Microenvironment by TGF-β Signaling Pathway
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 21, Issue 3, Pages 957
Publisher
MDPI AG
Online
2020-02-01
DOI
10.3390/ijms21030957
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Myofibroblasts in Pulmonary and Brain Metastases of Alveolar Soft-Part Sarcoma: A Novel Target for Treatment?
- (2015) Olga Genin et al. NEOPLASIA
- Mechanisms of tumor escape from immune system: Role of mesenchymal stromal cells
- (2014) Alessandro Poggi et al. IMMUNOLOGY LETTERS
- Low-dose metronomic chemotherapy: A systematic literature analysis
- (2013) K. Lien et al. EUROPEAN JOURNAL OF CANCER
- IQGAP1 suppresses TβRII-mediated myofibroblastic activation and metastatic growth in liver
- (2013) Chunsheng Liu et al. JOURNAL OF CLINICAL INVESTIGATION
- Targeted Therapy Resistance Mediated by Dynamic Regulation of Extrachromosomal Mutant EGFR DNA
- (2013) David A. Nathanson et al. SCIENCE
- Enhancing immunotherapy using chemotherapy and radiation to modify the tumor microenvironment
- (2013) Michael H Kershaw et al. OncoImmunology
- Metronomic chemotherapy with low-dose cyclophosphamide plus gemcitabine can induce anti-tumor T cell immunity in vivo
- (2012) Miki Tongu et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Dose-Dense Chemotherapy Improves Mechanisms of Antitumor Immune Response
- (2012) C.-L. Chang et al. CANCER RESEARCH
- Low-dose metronomic chemotherapy: from past experience to new paradigms in the treatment of cancer
- (2012) David Loven et al. DRUG DISCOVERY TODAY
- Adenosine as an endogenous immunoregulator in cancer pathogenesis: where to go?
- (2012) V. Kumar Purinergic Signalling
- Single low-dose cyclophosphamide combined with interleukin-12 gene therapy is superior to a metronomic schedule in inducing immunity against colorectal carcinoma in mice
- (2012) Mariana Malvicini et al. OncoImmunology
- Metronomic cyclophosphamide treatment in metastasized breast cancer patients: immunological effects and clinical outcome
- (2011) Yingzi Ge et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- TGF-β regulates isoform switching of FGF receptors and epithelial-mesenchymal transition
- (2011) Takuya Shirakihara et al. EMBO JOURNAL
- Immunological Effects of Low-dose Cyclophosphamide in Cancer Patients Treated With Oncolytic Adenovirus
- (2011) Vincenzo Cerullo et al. MOLECULAR THERAPY
- TGF-β: the sword, the wand, and the shield of FOXP3+ regulatory T cells
- (2011) Dat Q. Tran Journal of Molecular Cell Biology
- Curcumin reverses T cell-mediated adaptive immune dysfunctions in tumor-bearing hosts
- (2010) Sankar Bhattacharyya et al. Cellular & Molecular Immunology
- The Role of Regulatory T Cells in Cancer
- (2010) Tai-You Ha Immune Network
- Immunogenic chemotherapy with cyclophosphamide and doxorubicin against established murine carcinoma
- (2009) Miki Tongu et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- METRONOMIC CHEMOTHERAPY. CHANGING THE PARADIGM THAT MORE IS BETTER
- (2009) O.Graciela Scharovsky et al. Current Oncology
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More